[{"address1": "11400 West Olympic Boulevard", "address2": "Suite 200", "city": "Los Angeles", "state": "CA", "zip": "90064", "country": "United States", "phone": "310 651 8041", "website": "https://www.immixbio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.", "fullTimeEmployees": 14, "maxAge": 86400, "priceHint": 4, "previousClose": 1.92, "open": 1.89, "dayLow": 1.87, "dayHigh": 2.07, "regularMarketPreviousClose": 1.92, "regularMarketOpen": 1.89, "regularMarketDayLow": 1.87, "regularMarketDayHigh": 2.07, "beta": 0.199, "forwardPE": -2.0198019, "volume": 159032, "regularMarketVolume": 159032, "averageVolume": 126414, "averageVolume10days": 119820, "averageDailyVolume10Day": 119820, "bid": 2.0, "ask": 2.09, "bidSize": 100, "askSize": 100, "marketCap": 53885172, "fiftyTwoWeekLow": 1.55, "fiftyTwoWeekHigh": 7.75, "fiftyDayAverage": 2.2126, "twoHundredDayAverage": 3.546075, "currency": "USD", "enterpriseValue": 25375884, "floatShares": 13333146, "sharesOutstanding": 26414300, "sharesShort": 366483, "sharesShortPriorMonth": 349888, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.0139, "heldPercentInsiders": 0.41553003, "heldPercentInstitutions": 0.20469, "shortRatio": 2.55, "shortPercentOfFloat": 0.048499998, "impliedSharesOutstanding": 26414300, "bookValue": 1.058, "priceToBook": 1.9281664, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -18205376, "trailingEps": -0.93, "forwardEps": -1.01, "enterpriseToEbitda": -1.321, "52WeekChange": -0.16049385, "SandP52WeekChange": 0.26238096, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "IMMX", "underlyingSymbol": "IMMX", "shortName": "Immix Biopharma, Inc.", "longName": "Immix Biopharma, Inc.", "firstTradeDateEpochUtc": 1639665000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "a16f90b7-2d1a-3bc1-ad13-b52d1a275ae3", "messageBoardId": "finmb_417356223", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.04, "targetHighPrice": 14.0, "targetLowPrice": 14.0, "targetMeanPrice": 14.0, "targetMedianPrice": 14.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 1, "totalCash": 29319232, "totalCashPerShare": 1.11, "ebitda": -19202520, "totalDebt": 1093228, "quickRatio": 5.541, "currentRatio": 5.819, "debtToEquity": 3.956, "returnOnAssets": -0.50491, "returnOnEquity": -0.93615997, "freeCashflow": -7028939, "operatingCashflow": -13106288, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]